Europe Digital Dose Inhaler Market Size, Share & Industry Trends Analysis Report By Product (Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI)), By Type, By Indication (COPD, Asthma, and Others), By Country and Growth Forecast, 2023 - 2030

Europe Digital Dose Inhaler Market Size, Share & Industry Trends Analysis Report By Product (Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI)), By Type, By Indication (COPD, Asthma, and Others), By Country and Growth Forecast, 2023 - 2030

The Europe Digital Dose Inhaler Market would witness market growth of 19.1% CAGR during the forecast period (2023-2030).

The market is experiencing significant technological advancements that are revolutionizing inhalation therapy devices such as meters inhalers combined with an e-dose counter, internet-connected and compact inhalers, among others. To boost medication adherence and confirm that patients receive the correct dosage, the leading market participants primarily focus on connectivity technology. In addition, the rising demand for technologically advanced features such as patient monitoring and seamless data transfer adds the necessary elements to accelerate market growth.

Patients can self-administer using a digital dose inhaler by rapidly inhaling an aerosolized medication into their airways following a predetermined dose. Digital inhalers include sensors that monitor inspiratory flow and identify inhalers utilize following dose management and release. There are numerous varieties of digital dose inhalers on the market, including metric dose inhalers (MDI) and dry powder inhalers (DPI).

In England, smoking is one of the leading causes of health disparities, disproportionately impacting disadvantaged communities and groups. In 2019, approximately 13.9% of adults in England smoked, or about 6 million persons. In England, smoking is one of the primary preventable causes of disease and premature mortality, accounting for approximately 74,600 fatalities annually. Additionally, one in four hospitalized patients is a smoker. The prevalence of respiratory disorders will also increase in the region as the number of tobacco users rises. In addition, the prevalence of chronic obstructive pulmonary disease (COPD) in France is estimated to be 2.6 million, and it is anticipated to rise to 2.8 million by 2025. There needs to be more information regarding COPD management in private healthcare settings. These circumstances may increase the demand for products like digital dose inhalers.

The Germany market dominated the Europe Digital Dose Inhaler Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,045.8 million by 2030. The UK market is exhibiting a CAGR of 18.1% during (2023 - 2030). Additionally, The France market would experience a CAGR of 20% during (2023 - 2030).

Based on Product, the market is segmented into Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI). Based on Type, the market is segmented into Branded Medication, and Generic Medication. Based on Indication, the market is segmented into COPD, Asthma, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.

Scope of the Study

Market Segments covered in the Report:

By Product

• Metered Dose Inhaler (MDI)
• Dry Powder Inhaler (DPI)

By Type

• Branded Medication
• Generic Medication

By Indication

• COPD
• Asthma
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• Sensirion AG
• Teva Pharmaceuticals Industries Ltd.
• OPKO Health, Inc.
• Propeller Health (ResMed, Inc.)
• Novartis AG
• AstraZeneca PLC
• Glenmark Pharmaceuticals Limited
• Beximco Pharmaceuticals Ltd.
• GlaxoSmithKline PLC
• Mundipharma Deutschland GmbH & Co. KG

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free